Risks
4 risks
Risk Intelligence
Sustained dumping from China in low-end fluoropolymers
View Risks →Gujarat Fluorochemicals Limited — Q4 FY24
GFL reported Q4 FY24 consolidated revenue of INR 1,133 crore (up 14% QoQ) and EBITDA of INR 238 crore (up 15% QoQ), with margins flat at 21%.
neutral
medium
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
GFL reported Q4 FY24 consolidated revenue of INR 1,133 crore (up 14% QoQ) and EBITDA of INR 238 crore (up 15% QoQ), with margins flat at 21%. PAT stood at INR 101 crore (up 26% QoQ). The sequential recovery was driven by improved volumes in fluoropolymers and bulk chemicals, though pricing remained subdued in fluorochemicals and caustic soda. Management reiterated FY25 EBITDA guidance of ~INR 1,800-1,900 crore (similar to FY23), led by fluoropolymer growth from new capacities and market share gains from legacy player exits. Battery chemicals (LiPF6) are on track for commercial sales in H2 FY25, with INR 800 crore CapEx planned. Risks include sustained dumping in low-end fluoropolymers and delayed recovery in refrigerant pricing.
GFL ने चौथी तिमाही (वित्त वर्ष 24) में कुल कमाई 1,133 करोड़ रुपये बताई, जो पिछली तिमाही से 14% ज्यादा है। कंपनी की कमाई और खर्च का अंतर (EBITDA) 238 करोड़ रुपये रहा, जो 15% बढ़ा। मुनाफा (PAT) 101 करोड़ रुपये था, जो 26% ज्यादा है। यह सुधार फ्लोरोपॉलीमर और बल्क केमिकल्स की बिक्री बढ़ने से हुआ, लेकिन कुछ रसायनों के दाम कम रहे। कंपनी ने अगले साल 1,800-1,900 करोड़ रुपये का EBITDA लक्ष्य रखा है, जो नई क्षमताओं और बाजार हिस्सेदारी बढ़ने से मिलेगा। बैटरी केमिकल (LiPF6) की बिक्री अगले साल के दूसरे हाफ में शुरू होगी। 800 करोड़ रुपये का निवेश योजना है। जोखिमों में सस्ते आयात और रेफ्रिजरेंट के दाम में देरी शामिल है।
Risks4 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Fluoropolymer capacity utilization
Full capacity
Improving QoQ
Bulk chemical plants ran at full capacity in Q4, indicating volume recovery.
CapEx for battery chemicals in FY25
INR 800 crore
Flat vs FY24
Planned investment in LiPF6, cathode active materials, and binders for EV supply chain.
CapEx for GFL (non-EV) in FY25
INR 500 crore
Down from INR 1,050 crore in FY24
Tail-end spending on new fluoropolymer capacities and backward integration projects.
Asset turnover target for battery chemicals
2x
Guidance maintained
Management expects INR 2 of revenue for every INR 1 invested in battery chemicals over time.
What Changed vs Last Quarter
NEW
FY25 EBITDA to be similar to FY23 levels (~INR 1,800-1,900 crore)
Management expects EBITDA to recover to FY23 levels, driven by fluoropolymer volume growth and new capacity ramp-up.
NEW
Fluoropolymer segment to see continuous growth in FY25
Green shoots visible; destocking phasing out. New capacities in FKM, PFA, PVDF, and micropowders to drive volume and value growth.
UPDATED
Battery chemical commercial sales from H2 FY25
LiPF6 plant commissioned; sampling and customer engagement underway. Revenue expected to start trickling in from second half of FY25.
UPDATED
CapEx of INR 800 crore for battery chemicals in FY25
Funding to be raised externally; investment bankers appointed. CapEx plan remains on track.
DROPPED
FY25 EBITDA at par with FY23
Management revised guidance: FY25 EBITDA will be at similar levels to FY23 (INR ~1,900 crore), not higher, with a possible quarter variance.
DROPPED
Fluoropolymer capacity ramp-up over next 4 quarters
New fluoropolymer capacity (1,800-1,900 TPM) will be utilized over the next four quarters as approvals and customer validations progress.
NEW RISK
Sustained dumping from China in low-end fluoropolymers
Imports of lower-end grades (e.g., granular PTFE) continue to pressure domestic pricing and margins.
NEW RISK
Delayed recovery in refrigerant pricing
U.S. duty cuts and R-22 quota phase-out keep refrigerant prices subdued; no improvement expected in FY25.
NEW RISK
Funding risk for battery chemicals CapEx
Analyst raised concern about high net debt-to-EBITDA (1.8x) and INR 800 crore CapEx; management confirmed external funding process but no guarantee.
NEW RISK
Elevated operating costs impacting margins
Q4 operating costs rose due to year-end provisions, CSR, Red Sea logistics, and new plant expenses; sustainability unclear.
RISK GONE
Delayed destocking recovery in fluoropolymers
Legacy player inventory may take longer to deplete than expected, delaying volume recovery.
RISK GONE
Chinese dumping in specialty chemicals
Specialty chemical segment remains under pressure due to dumping from China, with no near-term improvement expected.
RISK GONE
EV business CapEx and dilution risk
Analyst raised concern about funding of EV CapEx and potential dilution; management deferred answer to separate EV call.
RISK GONE
FY25 EBITDA guidance revision
Management revised FY25 EBITDA guidance from 'better than FY23' to 'at par with FY23', indicating slower recovery.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q2 FY24, Q3 FY24
Management revised FY25 EBITDA guidance from 'better than FY23' to 'at par with FY23', indicating slower recovery.
Mentioned in Q1 FY24, Q3 FY24
Legacy player inventory may take longer to deplete than expected, delaying volume recovery.
Fast read
Guidance and risk preview
Management expects EBITDA to recover to FY23 levels, driven by fluoropolymer volume growth and new capacity ramp-up.
Imports of lower-end grades (e.g., granular PTFE) continue to pressure domestic pricing and margins.
View Risks →